HCM
VRCA icon

Heights Capital Management’s Verrica Pharmaceuticals VRCA Stock Holding History

Heights Capital Management’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-35,114
Closed -$246K – 143
2024
Q4 		$246K Buy
+35,114
New +$386K 0.12% 56

Other funds holding VRCA

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SA
Sovran Advisors San Diego, California $1.27B AUM 18.55% 1-Year Est. Return

Heights Capital Management's VRCA Position: Q1 2025 in Review

Heights Capital Management sold out of Verrica Pharmaceuticals (VRCA) in Q1 2025, closing a stake of 35,114 shares — an estimated $246K sold.

Heights Capital Management first reported a position in VRCA in Q4 2024 and held it in 1 quarter. The position peaked at $246K in Q4 2024. 74 funds tracked by Wall St. Rank hold VRCA as of Q1 2025.

  • Heights Capital Management reported no remaining Verrica Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Heights Capital Management sold 35,114 Verrica Pharmaceuticals shares in Q1 2025, an estimated $246K.
  • Heights Capital Management first reported a position in Verrica Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Heights Capital Management's Verrica Pharmaceuticals position peaked at $246K in Q4 2024.
  • 74 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q1 2025.

Based on Heights Capital Management's 13F filing for Q1 2025, filed 14 May 2025.